- Home
- SOS vs INAB Comparison
SOS vs INAB Comparison
Compare SOS & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOS
- INAB
- Stock Information
- Founded
- SOS 2004
- INAB 2016
- Country
- SOS China
- INAB United States
- Employees
- SOS N/A
- INAB N/A
- Industry
- SOS Finance: Consumer Services
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- SOS Finance
- INAB Health Care
- Exchange
- SOS Nasdaq
- INAB Nasdaq
- Market Cap
- SOS 10.7M
- INAB 10.6M
- IPO Year
- SOS 2017
- INAB 2021
- Fundamental
- Price
- SOS $1.75
- INAB $1.99
- Analyst Decision
- SOS
- INAB Strong Buy
- Analyst Count
- SOS 0
- INAB 2
- Target Price
- SOS N/A
- INAB $108.00
- AVG Volume (30 Days)
- SOS 90.8K
- INAB 61.1K
- Earning Date
- SOS 09-26-2025
- INAB 11-10-2025
- Dividend Yield
- SOS N/A
- INAB N/A
- EPS Growth
- SOS N/A
- INAB N/A
- EPS
- SOS N/A
- INAB N/A
- Revenue
- SOS $260,505,000.00
- INAB N/A
- Revenue This Year
- SOS N/A
- INAB N/A
- Revenue Next Year
- SOS N/A
- INAB N/A
- P/E Ratio
- SOS N/A
- INAB N/A
- Revenue Growth
- SOS 134.43
- INAB N/A
- 52 Week Low
- SOS $1.18
- INAB $1.91
- 52 Week High
- SOS $2.48
- INAB $12.53
- Technical
- Relative Strength Index (RSI)
- SOS 42.39
- INAB 36.11
- Support Level
- SOS $1.64
- INAB $1.95
- Resistance Level
- SOS $1.88
- INAB $2.15
- Average True Range (ATR)
- SOS 0.11
- INAB 0.09
- MACD
- SOS -0.01
- INAB -0.02
- Stochastic Oscillator
- SOS 27.44
- INAB 2.99
About SOS SOS Limited
SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing, cryptocurrency mining, and other services. The company has three reporting segments: Commodity trading, Cryptocurrency mining, and Others. Key revenue is generated from Commodity trading.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.